Meeting
2013 ASCO Annual Meeting
Correlation between anthropometric, pathologic data, and 21-gene recurrence score assay in early-stage breast cancer.
Authors
Keith Ian Quintyne
Mid-Western Cancer Centre, Limerick, Ireland
Keith Ian Quintyne , Bernie Woulfe , Linda Coate , Rajnish K. Gupta
Organizations
Mid-Western Cancer Centre, Limerick, Ireland, Mid-Western Regional Hospital, Limerick, Ireland
Research Funding
No funding sources reported
Background: Obesity or body mass index (BMI) > 30kg/m2 is a grave public health concern. Poorer outcome has been documented in obese breast cancer patients. We report the use of the Oncotype Dx Recurrence Score (RS) assay and its correlation with BMI and pathologic data. Methods: Study period: 01/09/08 – 31/05/12. Data was derived from: MWCC database; pathology reports; patient files; RS reports. Statistical analysis was carried out using R. Results: 89 patients were found. Median follow-up: 21.4 months. See Table for data. Conclusions: For this cohort: A skewed pattern in RS assay scores was observed in obese patients, where there were more intermediate and high scores, although this was not significant in multivariate model; tumour size and grade were shown to correlate with the RS assay results; these findings are thought-provoking and certainly can augment to the accruing energy balance data that has been increasingly of interest in oncological research.
| No. | Range | Median | RS |
Significance |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Low | Intermediate | High | Unknown | Univariate | Multivariate | ||||
| RS Assay U/k |
89 2 |
0–44 | 17 | 45 (51%) | 36 (40%) | 6 (7%) | |||
| Age (y) ≤ 44 45 – 54 55 – 64 ≥ 65 |
89 10 31 24 24 |
30.6–72.3 | 55.2 | 7 (70%) 16 (52%) 11 (46%) 11 (46%) |
2 (20%) 12 (39%) 12 (50%) 10 (42%) |
1 (10%) 1 (3%) 1 (4%) 3 (13%) |
0 (0%) 2 (6%) 0 (0%) 0 (0%) |
0.46 | 0.71 |
| Size (cm) ≤ 1.00 1.01 – 2.00 ≥ 2.01 |
89 8 54 27 |
0.8–5.0 | 1.7 | 3 (38%) 29 (54%) 13 (48%) |
3 (38%) 23 (43%) 10 (37%) |
1 (13%) 1 (2%) 4 (15%) |
1 (13%) 1 (2%) 0 (0%) |
0.02 | 0.06 |
| Histology Ductal Lobular Mixed |
89 72 16 1 |
38 (53%) 7 (44%) 0 (0%) |
28 (39%) 7 (44%) 1 (100%) |
5 (7%) 1 (6%) 0 (0%) |
1 (1%)1 (6%) 0 (0%) |
0.85 | 0.86 | ||
| Grade I II III |
89 8 74 7 |
1 (13%) 42 (57%) 2 (29%) |
7 (88%) 26 (35%) 3 (43%) |
0 (0%) 4 (5%) 2 (29%) |
0 (0%) 2 (3%) 0 (0%) |
0.04 | 0.04 | ||
| PgR +ve – ve |
89 78 11 |
43 (55%) 2 (18%) |
29 (37%) 7 (64%) |
5 (6%) 1 (9%) |
1 (1%) 1 (9%) |
0.11 | 0.09 | ||
| Menopause Pre Post U/k |
89 31 57 1 |
20 (65%) 25 (44%) 0 (0%) |
7 (23%) 28 (49%) 1 (100%) |
2 (6%) 4 (7%) 0 (0%) |
2 (6%) 0 (0%) 0 (0%) |
0.56 | 0.81 | ||
| Weight (kg) |
89 | 51–106 | 71.0 | 0.29 | |||||
| BMI (kg/m2) ≤ 25 25.1 – 30 ≥ 30.1 U/k |
89 31 31 24 3 |
20.0–44.1 | 27.2 | 19 (61%) 16 (52%) 9 (38%) 1 (33%) |
8 (26%) 13 (42%) 13 (54%) 2 (67%) |
3 (10%) 1 (3%) 2 (8%) 0 (0%) |
1 (3%) 1 (3%) 0 (0%) 0 (0%) |
0.02 | 0.13 |
* Unknown: U/k, PgR: progesterone receptor, +ve: positive, -ve: negative; % have been rounded and might not total 100%.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Cancer Prevention/Epidemiology
Track
Cancer Prevention/Epidemiology
Sub Track
Epidemiology
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1591)
DOI
10.1200/jco.2013.31.15_suppl.1591
Abstract #
1591
Poster Bd #
8D
Abstract Disclosures
Similar Abstracts
Abstract
2024 ASCO Annual Meeting
Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer.
First Author: Grace B Gallagher
Abstract
2022 ASCO Annual Meeting
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
First Author: Georg Pfeiler
Abstract
2021 ASCO Annual Meeting
Impact of African ancestry on the relationship between BMI and survival in early stage breast cancer: Retrospective analysis from E5103.
First Author: Tarah Jean Ballinger
Abstract
2023 ASCO Annual Meeting
Associations between body mass index with cancer recurrence and all-cause mortality among survivors of breast cancer.
First Author: Po-Hua Chen